{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+label&page=29",
    "query": {
      "intervention": "Control label",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 3339,
    "total_pages": 334,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+label&page=30&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+label&page=28&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T06:13:21.179Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01272960",
      "title": "Mirena Intrauterine System Timing of Insertion: A Randomized Controlled Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Postpartum Period"
      ],
      "interventions": [
        {
          "name": "Post-Placenta Mirena Insertion",
          "type": "DEVICE"
        },
        {
          "name": "Interval Insertion",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "14 Years to 45 Years · Female only"
      },
      "enrollment_count": 53,
      "start_date": "2010-10",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2017-12-02",
      "last_synced_at": "2026-10-23T06:13:21.179Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01272960"
    },
    {
      "nct_id": "NCT07808060",
      "title": "A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "Eloralintide",
          "type": "DRUG"
        },
        {
          "name": "Combined oral contraceptive",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 34,
      "start_date": "2026-09-15",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-23T06:13:21.179Z",
      "location_count": 2,
      "location_summary": "Daytona Beach, Florida • Dallas, Texas",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07808060"
    },
    {
      "nct_id": "NCT00142103",
      "title": "CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis, Chronic Active"
      ],
      "interventions": [
        {
          "name": "CPG10101",
          "type": "DRUG"
        },
        {
          "name": "Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2005-09",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2011-05-16",
      "last_synced_at": "2026-10-23T06:13:21.179Z",
      "location_count": 13,
      "location_summary": "Miami, Florida • Chicago, Illinois • Indianapolis, Indiana + 10 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00142103"
    },
    {
      "nct_id": "NCT04886518",
      "title": "Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myotonic Dystrophy 1",
        "Excessive Daytime Sleepiness"
      ],
      "interventions": [
        {
          "name": "Pitolisant Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Harmony Biosciences Management, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-06-28",
      "completion_date": "2024-10-31",
      "has_results": true,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-23T06:13:21.179Z",
      "location_count": 11,
      "location_summary": "Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04886518"
    },
    {
      "nct_id": "NCT01893190",
      "title": "Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ruptured Cerebral Aneurysm",
        "Ruptured Berry Aneurysm"
      ],
      "interventions": [
        {
          "name": "Nimodipine",
          "type": "DRUG"
        },
        {
          "name": "Nimodipine Microparticles",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Edge Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 73,
      "start_date": "2013-09",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2018-02-05",
      "last_synced_at": "2026-10-23T06:13:21.179Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01893190"
    },
    {
      "nct_id": "NCT02371746",
      "title": "Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma and Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "ENV515-3 Travoprost XR",
          "type": "DRUG"
        },
        {
          "name": "ENV515-1 Travoprost XR",
          "type": "DRUG"
        },
        {
          "name": "ENV515-3-2 Travoprost XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Envisia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 41,
      "start_date": "2015-01-01",
      "completion_date": "2019-02-13",
      "has_results": true,
      "last_update_posted_date": "2019-10-17",
      "last_synced_at": "2026-10-23T06:13:21.179Z",
      "location_count": 14,
      "location_summary": "Chandler, Arizona • Garden Grove, California • Inglewood, California + 11 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "Morrow",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02371746"
    },
    {
      "nct_id": "NCT00597727",
      "title": "A Study of Sublingual Immunotherapy in Peanut-allergic Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Food Hypersensitivity"
      ],
      "interventions": [
        {
          "name": "Peanut SLIT",
          "type": "DRUG"
        },
        {
          "name": "Placebo SLIT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "1 Year to 11 Years"
      },
      "enrollment_count": 60,
      "start_date": "2008-01",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2018-03-27",
      "last_synced_at": "2026-10-23T06:13:21.179Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00597727"
    },
    {
      "nct_id": "NCT05090891",
      "title": "To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fibrodysplasia Ossificans Progressiva (FOP)"
      ],
      "interventions": [
        {
          "name": "INCB000928",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "2 Years to 99 Years"
      },
      "enrollment_count": 98,
      "start_date": "2022-05-05",
      "completion_date": "2033-01-20",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-10-23T06:13:21.179Z",
      "location_count": 3,
      "location_summary": "Rochester, Minnesota • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05090891"
    },
    {
      "nct_id": "NCT00619190",
      "title": "Study of Aripiprazole to Treat Children and Adolescents With Autism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autistic Disorder",
        "Asperger Syndrome",
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "30 Months to 17 Years"
      },
      "enrollment_count": 30,
      "start_date": "2006-01",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2014-03-26",
      "last_synced_at": "2026-10-23T06:13:21.179Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00619190"
    },
    {
      "nct_id": "NCT01545050",
      "title": "Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Placebo matching with BMS-945429",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BMS-945429",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2012-06",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2021-12-03",
      "last_synced_at": "2026-10-23T06:13:21.179Z",
      "location_count": 8,
      "location_summary": "La Jolla, California • San Diego, California • Lone Tree, Colorado + 5 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01545050"
    }
  ]
}